New pill aims to fight fatigue in rare energy disorder
Symptom relief
Recruiting now
This study tests an experimental drug called KL1333 in 180 adults with primary mitochondrial disease, a condition that causes severe fatigue and muscle weakness. Participants will receive either KL1333 or a placebo for 48 weeks to see if the drug reduces tiredness and improves le…
Phase: PHASE2 • Sponsor: Abliva AB • Aim: Symptom relief
Last updated May 22, 2026 13:52 UTC